News | FDA | May 07, 2024

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

AngioFlow by RapidAI will facilitate confident clinical decision-making immediately prior to or after neuro-interventional procedures

AngioFlow by RapidAI will facilitate confident clinical decision-making immediately prior to or after neuro-interventional procedures

May 7, 2024 — RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced that the Food and Drug Administration (FDA) has granted 510(k) clearance for its AngioFlow by RapidAI solution. The module delivers perfusion imaging analysis directly within the interventional suite to promote greater clinical confidence, workflow efficiency, and potentially improve patient outcomes.

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”

In acute stroke care where time is brain, timely intervention can be not only life-saving but can significantly reduce the risk of long-term disability. Used by care teams working in the interventional suite, AngioFlow by RapidAI draws on validated deep clinical AI to deliver clear, easy-to-interpret qualitative perfusion maps within minutes to help specialists assess ischemic change in brain regions with reduced cerebral blood flow.

AngioFlow by RapidAI enhances operational efficiency and financial value by reducing redundant imaging and potentially saving time in patient care. Imaging at a referring facility allows physicians to evaluate the need for further scans in the interventional suite, accelerating clinical decisions and reducing unnecessary imaging. This is especially important in rural facilities and large hospital networks, where transfers may take hours to get from one facility to the next.

“AngioFlow by RapidAI will allow physicians to assess the need for additional imaging immediately in the interventional suite. By avoiding unnecessary scans, stroke patients can receive the timely care that can be the difference between being able to walk out of a hospital to their homes versus being discharged to a skilled nursing facility,” said Abhishek Singh, MD, DABPN, DUCNS at the Creighton University School of Medicine in Omaha, Nebraska.

For more information: https://www.rapidai.com/


Related Content

News | FDA

March 24, 2026 — Anumana has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary ...

Home March 31, 2026
Home
News | FDA

March 25, 2026 — Royal Philips has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator ...

Home March 27, 2026
Home
News | FDA

March 23, 2026 —Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for an expanded indication ...

Home March 24, 2026
Home
News | FDA

Feb. 27, 2026 — The U.S. Food and Drug Administration (FDA) has approved Abbott’s CardioMEMS Hero device — a pulmonary ...

Home February 27, 2026
Home
News | FDA

Feb. 17, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Retia Medical's Argos ...

Home February 17, 2026
Home
News | FDA

Jan. 13, 2026 – Innovative Health, Inc. has received its 50th clearance from FDA to reprocess single-use medical devices ...

Home January 15, 2026
Home
News | FDA

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

Home January 12, 2026
Home
News | FDA

Jan. 6, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the FDA approval of the Gore Viabahn ...

Home January 06, 2026
Home
News | FDA

Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt ...

Home January 05, 2026
Home
News | FDA

Dec. 18, 2025 — Huxley Medical has announced the SANSA home sleep apnea test has received regulatory clearance from the ...

Home December 19, 2025
Home
Subscribe Now